Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027937 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00027937: Completed Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
NCT00027937 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00027937, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Biological therapies such as interleukin-2 use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, peripheral stem cell transplantation, and interleukin-2 in treating patients who have solid tumors or lymphoma.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL aldesleukin
- BIOLOGICAL filgrastim
- DRUG busulfan
- BIOLOGICAL sargramostim
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-08 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
What the finished NCT00027937 record still lists
NCT00027937 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00027937 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00027937 about?
NCT00027937 is a clinical study titled "Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Biological therapies suc...
What is the current status of trial NCT00027937?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-08. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00027937?
The interventions under investigation include: cyclophosphamide (DRUG), aldesleukin (BIOLOGICAL), filgrastim (BIOLOGICAL), busulfan (DRUG), sargramostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00027937?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia